Literature DB >> 17254571

Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells.

Morichika Takita1, Masaki Inada, Takayuki Maruyama, Chisato Miyaura.   

Abstract

We examined the effects of prostaglandin E (PGE) receptor subtype EP4 antagonist on bone metastasis of cancer to clarify PGE's role in bone metastasis. Metastatic regions were detected in femurs accompanying severe bone loss in mice injected with B16 malignant melanoma cells. Administration of EP4 antagonist restored the bone loss induced by B16 melanoma. Adding B16 cells induced osteoclast formation in the coculture of bone marrow cells and osteoblasts without any exogenous bone-resorbing factor, and EP4 antagonist completely suppressed the osteoclast formation induced by B16 cells. Therefore, EP4 antagonist is a possible candidate for the therapy of bone metastasis of cancer.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17254571     DOI： 10.1016/j.febslet.2007.01.005

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  11 in total

1.  Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis.

Authors:  Masaki Inada; Morichika Takita; Satoshi Yokoyama; Kenta Watanabe; Tsukasa Tominari; Chiho Matsumoto; Michiko Hirata; Yoshiro Maru; Takayuki Maruyama; Yukihiko Sugimoto; Shuh Narumiya; Satoshi Uematsu; Shizuo Akira; Gillian Murphy; Hideaki Nagase; Chisato Miyaura
Journal:  J Biol Chem       Date:  2015-10-16       Impact factor: 5.157

Review 2.  Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.

Authors:  Aimalie L Hardaway; Mackenzie K Herroon; Erandi Rajagurubandara; Izabela Podgorski
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

3.  Inhibition of osteolytic bone metastasis by unfractionated heparin.

Authors:  Colin K Yee; Martin Butcher; Melec Zeadin; Jeffrey I Weitz; Stephen G Shaughnessy
Journal:  Clin Exp Metastasis       Date:  2008-09-24       Impact factor: 5.150

Review 4.  Prostaglandins in bone: bad cop, good cop?

Authors:  Katherine A Blackwell; Lawrence G Raisz; Carol C Pilbeam
Journal:  Trends Endocrinol Metab       Date:  2010-01-14       Impact factor: 12.015

Review 5.  Prostaglandin Pathways: Opportunities for Cancer Prevention and Therapy.

Authors:  Qiushi Wang; Rebecca J Morris; Ann M Bode; Tianshun Zhang
Journal:  Cancer Res       Date:  2022-03-15       Impact factor: 13.312

Review 6.  EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.

Authors:  Mousumi Majumder; Pinki Nandi; Ahmed Omar; Kingsley Chukwunonso Ugwuagbo; Peeyush K Lala
Journal:  Int J Mol Sci       Date:  2018-03-29       Impact factor: 5.923

Review 7.  The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone.

Authors:  Andy Göbel; Stefania Dell'Endice; Nikolai Jaschke; Sophie Pählig; Amna Shahid; Lorenz C Hofbauer; Tilman D Rachner
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

Review 8.  E-type prostanoid receptor 4 (EP4) in disease and therapy.

Authors:  Viktoria Konya; Gunther Marsche; Rufina Schuligoi; Akos Heinemann
Journal:  Pharmacol Ther       Date:  2013-03-21       Impact factor: 12.310

Review 9.  Eicosanoids in Cancer: Prostaglandin E2 Receptor 4 in Cancer Therapeutics and Immunotherapy.

Authors:  Mc Millan Ching; Jocelyn Reader; Amy M Fulton
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

Review 10.  Cellular and Molecular Mediators of Bone Metastatic Lesions.

Authors:  Giulia Battafarano; Michela Rossi; Francesco Marampon; Andrea Del Fattore
Journal:  Int J Mol Sci       Date:  2018-06-08       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.